Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study
Giannini S, Passeri G, Tripepi G, Sella S, Fusaro M, Arcidiacono G, Torres MO, Michielin A, Prandini T, Baffa V, Aghi A, Egan CG, Brigo M, Zaninotto M, Plebani M, Vettor R, Fioretto P, Rossini M, Vignali A, Fabris F, Bertoldo F
Nutrients · 53 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2021-01-14 · Nutrients · vol. 13 · número 1 · pág. 219
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 84 citas · más que el 96% de estudios similares · 5.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 66 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- COVID-19 Clinical Research Studies · Long-Term Effects of COVID-19 · Vitamin D Research Studies
- Palabras clave
- Medicine, Intensive care unit, Coronavirus disease 2019 (COVID-19), Cholecalciferol, Retrospective cohort study, Internal medicine, Vitamin D and neurology, Bolus (digestion), Gastroenterology, Pediatrics, Disease, Infectious disease (medical specialty)
- MeSH
- humans, vitamin d deficiency, cholecalciferol, vitamins, treatment outcome, hospitalization, injections, intravenous, retrospective studies, roc curve, adult, aged, aged, 80 and over, middle aged, female, male, covid-19, covid-19 drug treatment
21 autores
- Sandro Giannini🇮🇹 · autor de correspondenciaUniversity of Padua
- Giovanni Passeri🇮🇹University of Parma
- Giovanni Tripepi🇮🇹Istituto di Fisiologia Clinica; National Research Council
- Stefania Sella🇮🇹University of Padua
- Maria Fusaro🇮🇹University of Padua; Istituto di Fisiologia Clinica; National Research Council
- Gaetano Paride Arcidiacono🇮🇹University of Padua
- Marco Onofrio Torres🇮🇹University of Padua
- Alberto Michielin🇮🇹University of Padua
- Tancredi Prandini🇮🇹University of Padua
- Valeria Baffa🇮🇹University of Padua
- Andrea Aghi🇮🇹University of Padua
- Colin Gerard Egan
- Martina Brigo🇮🇹University of Verona
- Martina Zaninotto🇮🇹University of Padua
- Mario Plebani🇮🇹University of Padua
- Roberto Vettor🇮🇹University of Padua
- Paola Fioretto🇮🇹University of Padua
- Maurizio Rossini🇮🇹University of Verona
- Alessandro Vignali🇮🇹University of Parma
- Fabrizio Fabris🇮🇹University of Padua
- Francesco Bertoldo🇮🇹University of Verona
Resumen
El texto original del estudio, en el idioma en que se publicó.
Little information is available on the beneficial effects of cholecalciferol treatment in comorbid patients hospitalized for COVID-19. The aim of this study was to retrospectively examine the clinical outcome of patients receiving in-hospital high-dose bolus cholecalciferol. Patients with a positive diagnosis of SARS-CoV-2 and overt COVID-19, hospitalized from 15 March to 20 April 2020, were considered. Based on clinical characteristics, they were supplemented (or not) with 400,000 IU bolus oral cholecalciferol (200,000 IU administered in two consecutive days) and the composite outcome (transfer to intensive care unit; ICU and/or death) was recorded. Ninety-one patients (aged 74 ± 13 years) with COVID-19 were included in this retrospective study. Fifty (54.9%) patients presented with two or more comorbid diseases. Based on the decision of the referring physician, 36 (39.6%) patients were treated with vitamin D. Receiver operating characteristic curve analysis revealed a significant predictive power of the four variables: (a) low (p p = 0.033) and propensity score-adjusted analyses (p = 0.039), so the positive effect of high-dose cholecalciferol on the combined endpoint was significantly amplified with increasing comorbidity burden. This hypothesis-generating study warrants the formal evaluation (i.e., clinical trial) of the potential benefit that cholecalciferol can offer in these comorbid COVID-19 patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.